As shown in Figure 1C, either AKT or ERK inhibitor could significantly enhance the inhibitory effects of celastrol on CRC, especially those of low-dose celastrol (0.25–0.50 μM), which suggests a synergistic role. Here, AKT1 is linked to colorectal carcinoma.